Related Experiment Video
Updated: Jun 28, 2026
06:55
Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Hybrid risk adjustment for pharmaceutical benefits
Manuel García-Goñi1, Pere Ibern, José María Inoriza
1Departamento de Economía Aplicada II, Universidad Complutense de Madrid, Campus de Somosaguas, Pozuelo de Alarcón, 28223, Madrid, Spain. mggoni@ccee.ucm.es
Summary
Hybrid risk adjustment models improve healthcare efficiency by incentivizing better care for low-risk individuals and reducing drug spending variations. This approach enhances financial management in healthcare organizations.
Area of Science:
- Health Services Research
- Health Economics
- Pharmaceutical Policy
Background:
- Healthcare organizations face challenges in efficiently funding pharmaceutical benefits.
- Existing risk adjustment models (prospective and concurrent) have limitations in promoting efficiency.
- Integrated healthcare delivery systems require effective financial management tools.
Purpose of the Study:
- To analyze the application of hybrid risk adjustment compared to prospective or concurrent models.
- To evaluate the impact of hybrid risk adjustment on funding pharmaceutical benefits.
- To assess the effect on efficiency within an integrated healthcare delivery organization.
Main Methods:
- Application of a mixed (hybrid) risk adjustment formula.
- Analysis conducted within an integrated healthcare delivery organization in Catalonia.
- Data from the years 2002 and 2003 were utilized.
Main Results:
- Hybrid risk adjustment models increase incentives for efficiency, particularly for low-risk individuals.
- Compared to prospective-only models, hybrid models reduce within-group variation in drug expenditures.
- Efficiency gains are observed both at the organizational level and within internal departments.
Conclusions:
- Hybrid risk adjustment offers a superior approach to prospective or concurrent models for pharmaceutical benefit funding.
- This model promotes greater efficiency and better financial stewardship in healthcare delivery.
- The findings support the adoption of hybrid risk adjustment for optimizing drug expenditure management.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...